Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
In interviews with The American Journal of Managed Care®, Jennifer Graff, PharmD, of Innov8 Health Policy; Joey Mattingly, PharmD, MBA, PhD, of the University of Utah College of Pharmacy; and Brian ...
The symposium will present new research, including significant trials like HER2CLIMB-05, LidERA, and DESTINY-Breast11, through various sessions. SABCS 2025 will spotlight new advances in breast cancer ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.
Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results